Compare PBK & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBK | FEMY |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 22.4M |
| IPO Year | 2024 | 2021 |
| Metric | PBK | FEMY |
|---|---|---|
| Price | $0.28 | $2.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 672.6K | 67.0K |
| Earning Date | 09-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $171.32 | N/A |
| Revenue Next Year | $40.20 | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.26 | $0.29 |
| 52 Week High | $0.86 | $6.29 |
| Indicator | PBK | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 37.40 |
| Support Level | $0.26 | $0.41 |
| Resistance Level | $0.50 | $3.21 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 11.31 | 27.12 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.